Bedrijfsoverzicht
Nexentis Technologies Inc. operates within the Basic Materials sector, specifically focusing on the Agricultural Inputs industry, where it develops and operates an AI and data-driven computational biotech platform centered on mitochondrial biology, precision oncology, and inflammatory metabolic diseases. The company's business model relies on its proprietary MITOLINE discovery engine and structure-guided approaches to advance its technological capabilities in computational biology. As a publicly traded entity with the ticker NXTS, Nexentis holds a market capitalization of $3.10 million, reflecting its position as a micro-cap entity within the biotechnology landscape. With an employee count listed as N/A, the company's scale is defined primarily by its specialized intellectual property and limited financial resources rather than a large operational workforce, indicating a resource-constrained environment typical of early-stage biotech firms. The market cap of $3.10 million suggests that the company is valued based on high-risk, high-potential future developments rather than established cash flows or current revenue streams, positioning it as a speculative asset for investors seeking exposure to emerging biotech technologies.
Financiële gezondheid
The company reports a net income of $-3,443,000 and an EBITDA of $-5,295,000 over the trailing twelve months, while annual revenue figures are unavailable, highlighting a stage of development where operational losses are expected due to research and development expenditures. The significant gap between the reported revenue (N/A) and the negative net income reveals a cost structure heavily weighted towards R&D and platform development costs before any substantial commercial scaling occurs. Free cash flow stands at $-2,644,000, indicating that the company is burning cash to fuel its growth initiatives, which limits its immediate financial flexibility and reliance on external capital injections. Despite these operational deficits, the company maintains a substantial cash reserve of $4.07 million, providing a buffer against current burn rates, whereas total debt obligations are relatively low at $992,000. The balance sheet exhibits a debt-to-equity ratio of 6.31, a metric that typically suggests leverage but in the context of a pre-revenue biotech firm with negative earnings, reflects the use of equity financing to fund operations rather than traditional debt servicing. The current ratio is 4.19, which indicates a strong position regarding short-term liquidity and the ability to cover current liabilities with current assets, ensuring operational continuity despite the lack of positive operating cash flow. Return on Equity is -35.4% and Return on Assets is -25.9%, metrics that reveal the company is currently destroying value on a per-share and per-asset basis, which is characteristic of developmental companies but signals that management effectiveness is currently measured by asset accumulation and milestone achievement rather than profitability generation.
Waarderingsbeoordeling
Trailing P/E and forward P/E ratios are listed as N/A due to the company's negative net income and lack of projected earnings, which implies that traditional earnings-based valuation methods are inapplicable and that the market values the company based on asset backing and future potential rather than current profitability. The price-to-book ratio is 0.65, indicating that the market values the company at a discount to its book value, which often signals a undervaluation in distressed assets or a market skepticism regarding the convertibility of intangible assets like the MITOLINE platform into tangible equity value. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA of 0.05 are also not available or effectively zero due to the financial structure, suggesting that valuation is driven entirely by asset liquidation value or strategic optionality rather than revenue multiples. The stock trades within a wide range between a 52-week high of $205.80 and a 52-week low of $3.38, creating a volatility profile where the current price could theoretically sit anywhere within this spectrum depending on market sentiment and liquidity conditions. The beta value of 1.87 indicates that the stock price is highly volatile relative to the broader market, moving with greater intensity than the S&P 500, which aligns with the high-risk nature of small-cap biotechnology stocks that can experience significant price swings based on clinical trial results or funding news.
Growth & Income
Revenue growth and earnings growth rates are unavailable due to the N/A status of the revenue figure and the negative earnings trajectory, preventing a direct comparison of growth rates between the two metrics. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute profits to shareholders, which is consistent with its financial reality of having no positive net income to fund dividends. Instead of paying dividends, the company reinvests its remaining cash reserves into its computational biotech platform and research activities to advance its technology in mitochondrial biology and precision oncology. The overall growth and income profile is characterized by high financial risk and zero current income generation, relying on future potential rather than established growth or dividend yields to attract capital.